Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combination analgesic therapy consisting of three agents targeting mild-to-severe pain management via distinct mechanisms. Acetaminophen acts primarily through central nervous system pathways likely involving modulation at cyclooxygenase/prostanoid signaling centers resulting in antipyretic/analgesic effects without significant anti-inflammatory activity compared with traditional NSAIDs such as ketoprofen, which inhibit peripheral cyclooxygenases thereby reducing local inflammatory mediators responsible for tissue swelling/pain signals while also contributing systemic analgesia. Morphine's primary mode-of-action involves binding selectively onto mu-opioid receptors located throughout brain/spinal cord regions associated with nociceptive processing, thus producing profound suppression over subjective perception regarding painful stimuli. Used together they provide multimodal analgesia which can reduce total opioid requirement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen+ketoprofen+morphine.